1. Generics Bulletin
  2. >>Products

Biogen Delves Deeper Into Biosimilars With Tocilizumab Partnership

Signs Agreement With China’s Bio-Thera Solutions Worth Over $30m

 
• By Dean Rudge

Biogen has broken new ground in its biosimilar endeavors, expanding beyond its partnership with its part-owned Samsung Bioepis company by agreeing a deal for rights to Bio-Thera Solutions’ BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
Biogen has agreed to make an upfront payment of $30m to Bio-Thera Solutions, contingent upon Phase III data results • Source: Shutterstock

The traditionally innovative Biogen, Inc. is wading deeper into biosimilars, signing a global agreement outside of China with Bio-Thera Solutions Ltd. providing exclusive regulatory, manufacturing, and commercial rights to the Chinese firm’s BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.

The agreement for the proposed biosimilar to Genentech’s IL-6 receptor antagonist – which is currently in Phase III clinical development – covers all countries, excluding Bio-Thera

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.